Skye Bioscience, Inc.

NASDAQ: SKYE · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001516551Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 27DQ —GM —SS 45

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$55.9M

Employees

Market cap

$24.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$55.9M-$55.9M2025

Operating income-$58.2M-$58.2M2025

Total assets$28.3M$28.3M2025

Liabilities$8.3M$8.3M2025

Equity$20.0M$20.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Skye Bioscience, Inc. earned -$55.9M in FY2025 net income.

Peers · Healthcare

Cytosorbents Corporation55C HeartBeam, Inc.——TherapeuticsMD, Inc.60C Ocumetics Technology Corp.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Sempra$12.4B64C Realty Income Corporation$5.7B59C ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+DexCom, Inc.$4.7B87A

Key facts

CEOPunit Dhillon

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: SKYE

Employees12

IPO date2015-01-06

Latest filings

8-K2026-06-23 8-K2026-05-29 8-K2026-05-15 10-Q2026-05-11 DEF 14A2026-04-16 8-K2026-04-03 8-K2026-03-19 8-K2026-03-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.